ENPP1 inhibitor with ultralong drug-target residence time as an innate immune checkpoint blockade cancer therapy
8.4
来源：
Cell
关键字：
brain-inspired computing
发布时间：
2025-09-06 03:33
摘要：
STF-1623 is a potent ENPP1 inhibitor that enhances anti-tumor immunity by prolonging drug-target engagement in tumors while ensuring rapid systemic clearance. This innovative approach addresses the limitations of current immune checkpoint inhibitors by specifically targeting tumor-associated ENPP1, thus activating the STING pathway without systemic side effects. Preclinical studies demonstrate its efficacy across various cancer types, including breast, pancreatic, and colorectal cancers, indicating significant potential for clinical application and investment opportunities in the oncology sector.
原文：
查看原文
价值分投票
评分标准
新闻价值分采用0-10分制，综合考虑新闻的真实性、重要性、时效性、影响力等多个维度。
评分越高，表示该新闻的价值越大，越值得关注。
价值维度分析
domain_focus
1.0
business_impact
0.8
scientific_rigor
1.5
timeliness_innovation
1.5
investment_perspective
2.5
market_value_relevance
1.0
team_institution_background
0.5
technical_barrier_competition
0.7
关键证据
STF-1623 exhibits long tumor residence time and rapid systemic clearance.
Demonstrated robust anti-tumor effects across multiple cancer models.
Identified as a promising target for enhancing STING pathway activation.
真实性检查
否
AI评分总结
STF-1623 is a potent ENPP1 inhibitor that enhances anti-tumor immunity by prolonging drug-target engagement in tumors while ensuring rapid systemic clearance. This innovative approach addresses the limitations of current immune checkpoint inhibitors by specifically targeting tumor-associated ENPP1, thus activating the STING pathway without systemic side effects. Preclinical studies demonstrate its efficacy across various cancer types, including breast, pancreatic, and colorectal cancers, indicating significant potential for clinical application and investment opportunities in the oncology sector.